文献速递儿童呼吸儿童心血管与肾脏儿童神经与发育行为

唐氏综合征儿童肺动脉高压:儿科肺动脉高压网络登记研究

Pulmonary Hypertension in Children with Down Syndrome: Results from the Pediatric Pulmonary Hypertension Network Registry.
PubMed 文献 · J Pediatr · 2022-08-24

该多中心登记研究分析了1475例肺动脉高压患儿,其中158例(11%)合并唐氏综合征。唐氏综合征患儿诊断中位年龄为0.49年,先天性心脏病(95%)和睡眠呼吸暂停(56%)等合并症高发;3年时43%的肺动脉高压缓解,5年无移植生存率为88%。气管切开和抗反流药物使用与重度肺动脉高压复合结局独立相关。

要点

  • 唐氏综合征患儿肺动脉高压诊断中位年龄为0.49年,与无唐氏综合征患儿相似。
  • 唐氏综合征患儿先天性心脏病占95%,睡眠呼吸暂停占56%,早产占49%。
  • 3年时43%的肺动脉高压缓解,与诊断年龄<6个月和瓣前分流相关。

核心结论

  • 唐氏综合征相关肺动脉高压患儿尽管心脏和呼吸合并症发生率高,但生存率与非唐氏综合征相关肺动脉高压患儿相似。
  • 肺动脉高压缓解常见,但在合并复杂呼吸系统合并症的患儿中缓解率降低。

研究设计与样本

  • 研究分析了儿科肺动脉高压网络(PPHNet)登记数据,比较唐氏综合征与非唐氏综合征肺动脉高压患儿的人口学和临床特征。
  • 在唐氏综合征队列中分析了与肺动脉高压缓解及肺动脉高压严重程度复合结局相关的因素。

主要发现

  • 在1475例肺动脉高压患儿中,158例(11%)患有唐氏综合征,诊断时中位年龄为0.49年(IQR,0.21-1.77年)。
  • 唐氏综合征患儿合并症包括先天性心脏病(95%;其中68%已修复)、睡眠呼吸暂停(56%)、早产(49%)、反复呼吸道加重(35%)、胃食管反流(38%)和误吸(31%)。
  • 5年无移植生存率为88%(95%CI,80%-97%)。
  • 气管切开(风险比[HR],3.29;95%CI,1.61-6.69)和抗反流药物使用(HR,2.08;95%CI,1.11-3.90)与重度肺动脉高压复合结局独立相关。

临床怎么用

  • 对于唐氏综合征患儿,应关注肺动脉高压的早期诊断,尤其合并先天性心脏病和睡眠呼吸暂停时。
  • 气管切开和抗反流药物使用提示重度肺动脉高压复合结局风险较高,需加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize distinct comorbidities, outcomes, and treatment patterns in children with Down syndrome and pulmonary hypertension in a large, multicenter pediatric pulmonary hypertension registry. STUDY DESIGN: We analyzed data from the Pediatric Pulmonary Hypertension Network (PPHNet) Registry, comparing demographic and clinical characteristics of children with Down syndrome and children without Down syndrome. We examined factors associated with pulmonary hypertension resolution and a composite outcome of pulmonary hypertension severity in the cohort with Down syndrome. RESULTS: Of 1475 pediatric patients with pulmonary hypertension, 158 (11%) had Down syndrome. The median age at diagnosis of pulmonary hypertension in patients with Down syndrome was 0.49 year (IQR, 0.21-1.77 years), similar to that in patients without Down syndrome. There was no difference in rates of cardiac catheterization and prescribed pulmonary hypertension medications in children with Down syndrome and those without Down syndrome. Comorbidities in Down syndrome included congenital heart disease (95%; repaired in 68%), sleep apnea (56%), prematurity (49%), recurrent respiratory exacerbations (35%), gastroesophageal reflux (38%), and aspiration (31%). Pulmonary hypertension resolved in 43% after 3 years, associated with a diagnosis of pulmonary hypertension at age <6 months (54% vs 29%; P = .002) and a pretricuspid shunt (65% vs 38%; P = .02). Five-year transplantation-free survival was 88% (95% CI, 80%-97%). Tracheostomy (hazard ratio [HR], 3.29; 95% CI, 1.61-6.69) and reflux medication use (HR, 2.08; 95% CI, 1.11-3.90) were independently associated with a composite outcome of severe pulmonary hypertension. CONCLUSIONS: Despite high rates of cardiac and respiratory comorbidities that influence the severity of pulmonary hypertension, children with Down syndrome-associated pulmonary hypertension generally have a survival rate similar to that of children with non-Down syndrome-associated pulmonary hypertension. Resolution of pulmonary hypertension is common but reduced in children with complicated respiratory comorbidities.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Hopper RK, Abman SH, Elia EG, et al. Pulmonary Hypertension in Children with Down Syndrome: Results from the Pediatric Pulmonary Hypertension Network Registry. J Pediatr. 2022. PMID: 36027975. doi:10.1016/j.jpeds.2022.08.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。